Matches in SemOpenAlex for { <https://semopenalex.org/work/W2161631750> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W2161631750 endingPage "268" @default.
- W2161631750 startingPage "265" @default.
- W2161631750 abstract "Human papillomavirus (HPV) types 16 and 18 are responsible for approximately 70% of all cervix cancers, followed by HPV types 45 and 31, which represent an additional 10%. In total, there are 15 HPV types that have been associated with the development of cervical cancer [1,2]. HPV vaccination has been shown to be highly effective in preventing precancerous cervical lesions in several large, international, randomized trials [3–6]. A multivalent vaccine to all types of HPV known to cause cervical cancer may be ideal; however, the costs of large international studies may be prohibitive. There is evidence that cross-neutralization occurs, thereby broadening the coverage of the HPV vaccines and increasing the benefits of vaccine to a larger range of infected people. However, this concept remains controversial. This editorial reviews the evidence for cross-protection in current clinical trials, in vitro work and epidemiologic studies. Recently, Paavonen et al. published an interim analysis of a large, randomized, placebo-controlled trial of a HPV 16/18 L1 virus-like particle (VLP) vaccine [6]. While the primary end point was a decrease in high-grade cervical intraepithelial neoplasia (CIN 2+) associated with HPV 16 and 18, a decrease in persistent infections with other nonvaccine HPV types was also noted. This effect is termed ‘cross-protection.’ A decrease in persistent 6-month infections of 59.9 and 36.1% for HPV 45 and 31, respectively, was found, although this effect did not reach statistical significance against 12-month infections. Cross-protection of 31.6 and 46.5% was found for HPV 52 against 6and 12-month infections, respectively. Previous studies with longer follow-up (4.5 years) did not show protection against HPV 52, suggesting that this protective effect" @default.
- W2161631750 created "2016-06-24" @default.
- W2161631750 creator A5004367549 @default.
- W2161631750 creator A5041245755 @default.
- W2161631750 creator A5067709805 @default.
- W2161631750 date "2008-05-01" @default.
- W2161631750 modified "2023-09-26" @default.
- W2161631750 title "Cross-protection from human papillomavirus 16/18 against types 45 and 31: fact or fancy?" @default.
- W2161631750 cites W1561111148 @default.
- W2161631750 cites W1985584979 @default.
- W2161631750 cites W2007706099 @default.
- W2161631750 cites W2009115624 @default.
- W2161631750 cites W2010311675 @default.
- W2161631750 cites W2026322085 @default.
- W2161631750 cites W2069794080 @default.
- W2161631750 cites W2093480157 @default.
- W2161631750 cites W2098491904 @default.
- W2161631750 cites W2100884338 @default.
- W2161631750 cites W2101196984 @default.
- W2161631750 cites W2112859230 @default.
- W2161631750 cites W2127043059 @default.
- W2161631750 cites W2131310491 @default.
- W2161631750 cites W2145426305 @default.
- W2161631750 cites W2152341463 @default.
- W2161631750 cites W2154262967 @default.
- W2161631750 cites W2159831861 @default.
- W2161631750 cites W2160498668 @default.
- W2161631750 cites W2160808472 @default.
- W2161631750 doi "https://doi.org/10.2217/14750708.5.3.265" @default.
- W2161631750 hasPublicationYear "2008" @default.
- W2161631750 type Work @default.
- W2161631750 sameAs 2161631750 @default.
- W2161631750 citedByCount "3" @default.
- W2161631750 crossrefType "journal-article" @default.
- W2161631750 hasAuthorship W2161631750A5004367549 @default.
- W2161631750 hasAuthorship W2161631750A5041245755 @default.
- W2161631750 hasAuthorship W2161631750A5067709805 @default.
- W2161631750 hasConcept C126322002 @default.
- W2161631750 hasConcept C159047783 @default.
- W2161631750 hasConcept C2994532551 @default.
- W2161631750 hasConcept C71924100 @default.
- W2161631750 hasConceptScore W2161631750C126322002 @default.
- W2161631750 hasConceptScore W2161631750C159047783 @default.
- W2161631750 hasConceptScore W2161631750C2994532551 @default.
- W2161631750 hasConceptScore W2161631750C71924100 @default.
- W2161631750 hasIssue "3" @default.
- W2161631750 hasLocation W21616317501 @default.
- W2161631750 hasOpenAccess W2161631750 @default.
- W2161631750 hasPrimaryLocation W21616317501 @default.
- W2161631750 hasRelatedWork W2051450136 @default.
- W2161631750 hasRelatedWork W2083662861 @default.
- W2161631750 hasRelatedWork W2286133478 @default.
- W2161631750 hasRelatedWork W2418672514 @default.
- W2161631750 hasRelatedWork W4234408046 @default.
- W2161631750 hasRelatedWork W4235324391 @default.
- W2161631750 hasRelatedWork W4253931720 @default.
- W2161631750 hasRelatedWork W4255562108 @default.
- W2161631750 hasRelatedWork W4322706520 @default.
- W2161631750 hasRelatedWork W2992699506 @default.
- W2161631750 hasVolume "5" @default.
- W2161631750 isParatext "false" @default.
- W2161631750 isRetracted "false" @default.
- W2161631750 magId "2161631750" @default.
- W2161631750 workType "article" @default.